제약·바이오테크놀러지용 웨어러블 디바이스 시장 예측(-2031년) : 제품별, 치료 분야별, 용도별, 최종사용자별, 지역별

The wearables in pharma & biotech market is projected to reach USD 9.97 billion by 2031 from USD 3.98 billion in 2026, at a CAGR of 20.2%. The market is driven by rapid technological developments in biosensors, miniaturization, and digitization. Increasing global digital connectivity is another significant facilitator of the expanding wearable market. The International Telecommunication Union reported that over 5.4 billion people worldwide were using the internet in 2023. This widespread connectivity is enabling the seamless integration of data from wearable devices into cloud environments.

Additionally, the All of Us Research Program has recruited more than 500,000 participants, some of whom are contributing data from wearables, including activity levels, heart rate, and sleep patterns. This reflects the growing role of wearable technology in large-scale biomedical research and precision medicine. This growth is further supported by the increasing adoption of remote patient monitoring (RPM) and digital care solutions. In the US, the Centers for Medicare & Medicaid Services reported a substantial increase in reimbursement claims for remote physiological monitoring services following the expansion of the policy in 2022. This indicates widespread adoption of wearable-derived care among healthcare providers. In addition, developments in the accuracy of sensors and multi-parameter monitoring are allowing wearables to measure clinically significant endpoints beyond basic vital signs. This is expanding the scope of wearables in drug safety and therapeutic studies.

"By product, continuous glucose monitors (CGMs) segment to account for largest market share"

The product segment is divided into smartwatches, fitness bands, smart rings, continuous glucose monitors (CGMs), patches, wearable injectors, and others. The CGMs segment has a large market share due to the high level of support from clinical guidelines, increasing scope of eligible patients, and the ability of the devices to be used with the most advanced diabetic management systems. The American Diabetes Association recommends the use of CGMs for a broad population of diabetic patients, as per the 2024 Standards of Care, thereby increasing the scope of the market. Furthermore, the availability of reimbursement schemes for hundreds of thousands of patients through the National Health Service has also helped the market expand in the region. In addition, approvals by the Food and Drug Administration for interoperable CGMs used in conjunction with insulin delivery systems have also helped the market expand in the region. The devices also provide up to 288 glucose readings in a day, making them highly valuable in the market .

"By end user, pharmaceutical and biotech companies accounted for largest market share in 2025"

Pharmaceutical and biotech companies dominated the market for wearables in the pharma & biotech market in terms of market share in 2025. This is mainly attributed to the complexity of clinical trials, where pharmaceutical and biotech companies require wearable technologies for data collection. According to a study by the Tufts Center for the Study of Drug Development, clinical trial protocols currently involve more than 20 endpoints on average, thus increasing the requirement for data collection. Wearable technologies are increasingly being used in this context. Furthermore, large-scale research initiatives, such as the UK Biobank, have successfully used wearable technologies for data collection from over 100,000 individuals, thus highlighting the potential of wearable technologies in pharmaceutical research. Considering this, pharmaceutical and biotech companies are likely to remain a dominant end user in this market .

"Asia Pacific to witness highest growth rate during forecast period"

The Asia Pacific (APAC) region is experiencing the highest growth rate in the wearables in pharma & biotech market. This growth can be attributed to several factors, including improvements in digital health infrastructure, a rise in clinical research activities, and a significant number of underserved patients. According to the WHO, the combined Western Pacific and Southeast Asia regions contribute a large share to the world's disease burden. It has been mentioned by the International Telecommunication Union that the penetration of the Internet in the APAC region has surpassed 66% to 70% in recent years. Additionally, it has been observed that countries like China and India are emerging as hubs for clinical trials, with thousands of trials already conducted in these regions. Technology is being adopted to enhance the efficiency of these trials. In September 2024, Biobeat announced its expansion into Argentina and Chile through a partnership with Infinity Pharma.

The breakdown of primary participants is as given below:

• By Company Type - Tier 1: 60%, Tier 2: 30%, and Tier 3: 10%
• By Designation - C-level: 30%, Director-level: 50%, and Others: 20%
• By Region - North America: 45%, Europe: 20%, Asia Pacific: 25%, Rest of the World: 10%.

Abbott (US), Dexcom, Inc. (US), and Masimo (US) are some of the key players in the wearables in pharma & biotech market.

• The study includes an in-depth competitive analysis of these key players in the wearables in pharma & biotech market, with their company profiles, recent developments, and key market strategies.

Research Coverage

This research report categorizes the wearables in pharma & biotech market by Product (Smartwatches, Fitness Bands, Smart Rings, Continuous Glucose Monitors (CGM), Patches, Wearable Injectors, Others), Therapeutic Area (cardiovascular (atherosclerotic cardiovascular disease (ASCVD) / secondary prevention, heart failure (HFREF and HFPEF), hypertension, atrial fibrillation (AF) / stroke prevention, pulmonary hypertension, structural heart disease / interventional cardiology), oncology (solid tumors, hematologic malignancies), diabetes, mental health & behavioral health, respiratory disorders, lifestyle & wellness improvement, neurology, musculoskeletal disorders / pain management, women's health & reproductive health, other diseases), Application (drug discovery, clinical trials (phase ii, phase iii, phase iv), medication adherence & behavioral support, chronic disease monitoring, personalized & preventive digital therapeutics), end user (pharmaceutical & biotech companies, healthcare providers & clinicians, other end users), and region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the wearables in pharma & biotech market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; contracts, partnerships, agreements, new product & service launches, mergers & acquisitions, and recent developments associated with the wearables in pharma & biotech market. Competitive analysis of upcoming startups in the market ecosystem is covered in this report.

Reasons to Buy this Report

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the wearables in pharma & biotech market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and to plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Shift toward value-based and patient-centric healthcare models, Rising prevalence of chronic diseases requiring continuous patient monitoring, Rapid digitalization of healthcare and expansion of telehealth services) restraints (High implementation and integration costs for healthcare providers, Data privacy and cybersecurity concerns) opportunities (Expansion of remote patient monitoring and home-based care models, Integration of advanced analytics and personalized healthcare) and challenges (Interoperability limitations with existing healthcare IT systems, Low patient adoption and digital literacy barriers) influencing the growth of the wearables in pharma & biotech market
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the wearables in pharma & biotech market
• Market Development: Comprehensive information about lucrative markets; the report analyses the wearables in pharma & biotech market across varied regions.
• Market Diversification: Exhaustive information about new products & services, untapped geographies, recent developments, and investments in the wearables in pharma & biotech market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like BD (US), Abbott (US), Masimo (US), DexCom, Inc. (US), Medtronic (Ireland), among others, in the wearables in pharma & biotech market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 UNIT CONSIDERED
• 1.6 STAKEHOLDERS

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING WEARABLES IN PHARMA & BIOTECH MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 ATTRACTIVE OPPORTUNITIES FOR WEARABLES IN PHARMA & BIOTECH MARKET
• 3.2 NORTH AMERICA WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER AND COUNTRY
• 3.3 WEARABLES IN PHARMA & BIOTECH MARKET, BY COUNTRY

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Shift toward value-based and patient-centric healthcare models
    • 4.2.1.2 Prevalence of chronic diseases requiring continuous patient monitoring
    • 4.2.1.3 Rapid digitalization of healthcare and expansion of telehealth services
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High implementation and integration costs
    • 4.2.2.2 Data privacy and cybersecurity concerns
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Expansion of remote patient monitoring and home-based care models
    • 4.2.3.2 Integration of advanced analytics and personalized healthcare
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Limited interoperability with existing healthcare IT systems
    • 4.2.4.2 Low patient adoption and digital literacy barriers
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 BARGAINING POWER OF SUPPLIERS (MODERATE)
  • 5.1.2 BARGAINING POWER OF BUYERS (MODERATE TO HIGH)
  • 5.1.3 THREAT OF SUBSTITUTES (LOW TO MODERATE)
  • 5.1.4 THREAT OF NEW ENTRANTS (MODERATE)
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY (HIGH)
• 5.2 MACROECONOMIC INDICATORS
  • 5.2.1 GDP TRENDS AND FORECAST
  • 5.2.2 TRENDS IN GLOBAL HEALTHCARE IT INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 INDICATIVE PRICING ANALYSIS OF KEY PLAYERS, BY PRODUCT, 2025
  • 5.5.2 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
• 5.6 TRADE ANALYSIS
  • 5.6.1 IMPORT DATA (HS CODE 9018)
  • 5.6.2 EXPORT DATA (HS CODE 9018)
• 5.7 KEY CONFERENCES AND EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 CASE STUDY ANALYSIS
• 5.11 IMPACT OF 2025 US TARIFF
  • 5.11.1 KEY TARIFF RATES
  • 5.11.2 PRICE IMPACT ANALYSIS
  • 5.11.3 IMPACT ON COUNTRIES/REGIONS
    • 5.11.3.1 US
    • 5.11.3.2 Europe
    • 5.11.3.3 Asia Pacific
  • 5.11.4 IMPACT ON END-USE INDUSTRIES
    • 5.11.4.1 Pharmaceutical & biotech companies
    • 5.11.4.2 Healthcare providers & clinicians
    • 5.11.4.3 Other end users

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 ADVANCED BIOSENSING AND MULTI-PARAMETER WEARABLES
  • 6.1.2 AI-DRIVEN ANALYTICS AND CLINICAL INTELLIGENCE
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 MOBILE HEALTH AND REMOTE PATIENT MONITORING
  • 6.2.2 ANALYTICS AND POPULATION-LEVEL HEALTH DATA INTEGRATION
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 INTERNET OF MEDICAL THINGS AND CONNECTED DEVICES
  • 6.3.2 CLOUD AND EDGE COMPUTING
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
• 6.5 PATENT ANALYSIS
  • 6.5.1 PATENT PUBLICATION TRENDS
  • 6.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 AI-DRIVEN PREDICTIVE MONITORING AND CLINICAL DECISION SUPPORT
  • 6.6.2 CLOSED-LOOP THERAPEUTIC AND DRUG DELIVERY SYSTEMS
  • 6.6.3 DECENTRALIZED AND HYBRID CLINICAL TRIAL ENABLEMENT
  • 6.6.4 CONTINUOUS DISEASE MANAGEMENT AND PREVENTIVE HEALTHCARE
  • 6.6.5 ADVANCED BIOSENSING AND NON-INVASIVE DIAGNOSTICS
  • 6.6.6 INTEGRATION WITH DIGITAL THERAPEUTICS AND PERSONALIZED MEDICINE
• 6.7 IMPACT OF AI/GEN AI
  • 6.7.1 MARKET POTENTIAL OF AI/GEN AI
  • 6.7.2 CASE STUDIES RELATED TO AI/GEN AI IMPLEMENTATION
    • 6.7.2.1 AI-driven continuous glucose monitoring and diabetes management at Dexcom
  • 6.7.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
    • 6.7.3.1 Wearable data analytics and AI-driven monitoring platforms
    • 6.7.3.2 Digital health platforms, integration, and regulatory infrastructure
    • 6.7.3.3 Clinical care, remote monitoring, and personalized therapeutics
  • 6.7.4 USER READINESS AND IMPACT ASSESSMENT
    • 6.7.4.1 User readiness
      • 6.7.4.1.1 User A: Hospitals, clinics, and long-term care providers
      • 6.7.4.1.2 User B: Pharma and biotech companies
    • 6.7.4.2 Impact assessment
      • 6.7.4.2.1 User A: Hospitals, clinics, and long-term care providers
        • 6.7.4.2.1.1 Implementation
        • 6.7.4.2.1.2 Impact
      • 6.7.4.2.2 User B: Pharma and biotech companies
        • 6.7.4.2.2.1 Implementation
        • 6.7.4.2.2.2 Impact

7 REGULATORY LANDSCAPE

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM END-USE INDUSTRIES
  • 8.4.1 UNMET NEEDS
  • 8.4.2 END-USER EXPECTATIONS
• 8.5 MARKET PROFITABILITY

9 WEARABLES IN PHARMA & BIOTECH MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 SMARTWATCHES
  • 9.2.1 EXPANDING ROLE IN DIGITAL CLINICAL TRIALS AND REMOTE MONITORING
• 9.3 FITNESS BANDS
  • 9.3.1 EMPHASIS ON REAL-WORLD EVIDENCE AND PATIENT-CENTRIC TRIAL DESIGNS
• 9.4 SMART RINGS
  • 9.4.1 EMERGING CLINICAL-GRADE WEARABLES ENABLING EARLY DISEASE DETECTION AND CONTINUOUS MONITORING
• 9.5 CONTINUOUS GLUCOSE MONITORS
  • 9.5.1 TRANSFORMING METABOLIC RESEARCH THROUGH REAL-TIME, HIGH-FREQUENCY DATA
• 9.6 PATCHES
  • 9.6.1 CONTINUOUS, CLINICAL-GRADE MONITORING DRIVING ADOPTION IN DECENTRALIZED TRIALS
• 9.7 WEARABLE INJECTORS
  • 9.7.1 GROWING DEMAND FOR SELF-ADMINISTRATION OF BIOLOGICS IN CHRONIC DISEASE MANAGEMENT
• 9.8 OTHER PRODUCTS

10 WEARABLES IN PHARMA & BIOTECH MARKET, BY THERAPEUTIC AREA

• 10.1 INTRODUCTION
• 10.2 CARDIOVASCULAR
  • 10.2.1 ATHEROSCLEROTIC CARDIOVASCULAR DISEASES/SECONDARY PREVENTION
    • 10.2.1.1 Focus on improving endpoint capture and long-term outcomes monitoring
  • 10.2.2 HEART FAILURE
    • 10.2.2.1 Continuous physiologic monitoring and AI-enabled decompensation prediction
  • 10.2.3 HYPERTENSION
    • 10.2.3.1 Cuffless monitoring and AI-driven adherence management enabling precision blood pressure control
  • 10.2.4 ATRIAL FIBRILLATION/STROKE PREVENTION
    • 10.2.4.1 Rapid expansion of AI-powered arrhythmia detection algorithms and regulatory-cleared wearable ECG technologies
  • 10.2.5 PULMONARY HYPERTENSION
    • 10.2.5.1 Growing use of wearable-enabled remote monitoring and AI analytics to generate objective, real-world functional endpoints
  • 10.2.6 STRUCTURAL HEART DISEASES/INTERVENTIONAL CARDIOLOGY
    • 10.2.6.1 Wearable-enabled remote recovery monitoring and procedural optimization supporting precision structural heart care
• 10.3 ONCOLOGY
  • 10.3.1 SOLID TUMORS
    • 10.3.1.1 BREAST CANCER
      • 10.3.1.1.1 Continuous wearable-based survivorship monitoring and decentralized oncology trials driving personalized long-term care models
    • 10.3.1.2 LUNG CANCER
      • 10.3.1.2.1 Constant respiratory monitoring and decentralized trial adoption
    • 10.3.1.3 PROSTATE CANCER
      • 10.3.1.3.1 Expansion of decentralized oncology trials and long-term survivorship management
    • 10.3.1.4 COLORECTAL CANCER
      • 10.3.1.4.1 Increasing adoption of decentralized oncology trials and remote post-surgical monitoring
    • 10.3.1.5 BRAIN TUMOR
      • 10.3.1.5.1 Remote neurologic surveillance and functional recovery tracking accelerating personalized care
    • 10.3.1.6 OTHER SOLID TUMORS
  • 10.3.2 HEMATOLOGIC MALIGNANCIES
    • 10.3.2.1 LEUKEMIA
      • 10.3.2.1.1 Wearable-enabled infection surveillance and treatment resilience monitoring transforming outpatient care
    • 10.3.2.2 LYMPHOMA
      • 10.3.2.2.1 Shift toward outpatient infusion centers, home-based recovery, and decentralized clinical trials
    • 10.3.2.3 MULTIPLE MYELOMA
      • 10.3.2.3.1 Real-time toxicity and mobility tracking using wearables in long-term management
    • 10.3.2.4 OTHER HEMATOLOGIC MALIGNANCIES
  • 10.3.3 DIABETES
    • 10.3.3.1 Critical need for long-term, real-world metabolic monitoring
  • 10.3.4 MENTAL HEALTH & BEHAVIORAL HEALTH
    • 10.3.4.1 Rising global burden of psychiatric disorders
  • 10.3.5 RESPIRATORY DISORDERS
    • 10.3.5.1 Early exacerbation detection through continuous monitoring reduces hospitalization
  • 10.3.6 LIFESTYLE & WELLNESS IMPROVEMENT
    • 10.3.6.1 Continuous tracking for lifestyle optimization and preventive health risk management
  • 10.3.7 NEUROLOGY
    • 10.3.7.1 Wearable-based monitoring of neurological function and digital clinical endpoints in CNS disorders
  • 10.3.8 MUSCULOSKELETAL DISORDERS/PAIN MANAGEMENT
    • 10.3.8.1 Wearable-guided functional movement and chronic pain monitoring in musculoskeletal disorders
  • 10.3.9 WOMEN'S HEALTH & REPRODUCTIVE HEALTH
    • 10.3.9.1 Continuous physiological and reproductive cycle using wearables
  • 10.3.10 OTHER DISEASES

11 WEARABLES IN PHARMA & BIOTECH MARKET, BY APPLICATION

• 11.1 INTRODUCTION
• 11.2 DRUG DISCOVERY
  • 11.2.1 RECENT ADVANCES PROMOTE DISCOVERY OF DRUGS THROUGH WEARABLES IN PHARMA & BIOTECH
• 11.3 CLINICAL TRIALS
  • 11.3.1 PHASE II
    • 11.3.1.1 AI-enabled remote monitoring and adaptive trial designs accelerate adoption
  • 11.3.2 PHASE III
    • 11.3.2.1 Rapid expansion of decentralized and hybrid global trial models propels growth
  • 11.3.3 PHASE IV
    • 11.3.3.1 Ability to improve patient engagement and retention in long-duration studies drives market
• 11.4 MEDICATION ADHERENCE & BEHAVIORAL SUPPORT
  • 11.4.1 CONNECTED REMINDERS, PASSIVE MONITORING, AND PERSONALIZED NUDGES BOOST ADOPTION
• 11.5 CHRONIC DISEASE MONITORING
  • 11.5.1 CONTINUOUS PHYSIOLOGICAL TRACKING AND PROACTIVE INTERVENTION CAPABILITIES INCREASE ADOPTION
• 11.6 PERSONALIZED & PREVENTIVE DIGITAL THERAPEUTICS
  • 11.6.1 BIOMETRIC SENSING AND AI-DRIVEN COACHING RAISE DEMAND FOR WEARABLES

12 WEARABLES IN PHARMA & BIOTECH MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 PHARMACEUTICAL & BIOTECH COMPANIES
  • 12.2.1 CLINICAL DIGITIZATION, REAL-WORLD EVIDENCE GENERATION, AND CONNECTED THERAPY MODELS DRIVE MARKET
• 12.3 HEALTHCARE PROVIDERS & CLINICIANS
  • 12.3.1 REMOTE PATIENT MONITORING, PREVENTIVE CARE, AND DATA-DRIVEN CLINICAL DECISION SUPPORT BOOST GROWTH
• 12.4 CONTRACT RESEARCH ORGANIZATIONS
  • 12.4.1 DECENTRALIZED TRIALS, WEARABLE DATA INTEGRATION, AND FASTER CLINICAL EXECUTION RAISE DEMAND
• 12.5 OTHER END USERS

13 WEARABLES IN PHARMA & BIOTECH MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 US
    • 13.2.1.1 High concentration of clinical research activity, clinical trial inefficiencies, and cost pressures to drive market
  • 13.2.2 CANADA
    • 13.2.2.1 Clinical research participation, public health burden, and digital health adoption to drive market
• 13.3 EUROPE
  • 13.3.1 GERMANY
    • 13.3.1.1 Expanding clinical trial activity and regulatory leadership to drive market
  • 13.3.2 FRANCE
    • 13.3.2.1 Regulatory-first approach to healthcare and clinical innovation to drive market
  • 13.3.3 UK
    • 13.3.3.1 Real-world data integration and decentralized trial innovation to drive market
  • 13.3.4 ITALY
    • 13.3.4.1 Evolving clinical trial landscape and regulatory decentralization to drive market
  • 13.3.5 SPAIN
    • 13.3.5.1 Increasing investment in digital health infrastructure to drive market
  • 13.3.6 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 CHINA
    • 13.4.1.1 Clinical trial expansion and real-world data integration to drive market
  • 13.4.2 JAPAN
    • 13.4.2.1 Late-stage trial leadership and regulatory precision to drive market
  • 13.4.3 INDIA
    • 13.4.3.1 High-volume Phase III trial ecosystem and ABDM-driven digital health integration to drive market
  • 13.4.4 AUSTRALIA
    • 13.4.4.1 Early-phase trial leadership and remote care needs to drive market
  • 13.4.5 SOUTH KOREA
    • 13.4.5.1 Integrated clinical trial ecosystem and national health data infrastructure to drive market
  • 13.4.6 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 BRAZIL
    • 13.5.1.1 Clinical trial leadership and high diabetes burden to drive market
  • 13.5.2 MEXICO
    • 13.5.2.1 Regulatory reforms and Phase III trial expansion to drive market
  • 13.5.3 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 GCC
  • 13.6.2 SAUDI ARABIA
    • 13.6.2.1 Vision 2030-led digital health transformation to drive market
  • 13.6.3 UAE
    • 13.6.3.1 Digital health strategy, clinical trial expansion, and high healthcare investment to drive market
  • 13.6.4 REST OF GCC
  • 13.6.5 SOUTH AFRICA
    • 13.6.5.1 Clinical trial leadership and decentralized care models to drive market
  • 13.6.6 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 OVERVIEW
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
• 14.3 REVENUE ANALYSIS, 2021-2025
• 14.4 MARKET SHARE ANALYSIS, 2025
• 14.5 BRAND/PRODUCT COMPARISON
• 14.6 COMPANY VALUATION AND FINANCIAL METRICS
• 14.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 14.7.1 STARS
  • 14.7.2 EMERGING LEADERS
  • 14.7.3 PERVASIVE PLAYERS
  • 14.7.4 PARTICIPANTS
  • 14.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 14.7.5.1 Company footprint
    • 14.7.5.2 Region footprint
    • 14.7.5.3 Product footprint
    • 14.7.5.4 Therapeutic area footprint
    • 14.7.5.5 Application footprint
    • 14.7.5.6 End user footprint
• 14.8 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2025
  • 14.8.1 PROGRESSIVE COMPANIES
  • 14.8.2 RESPONSIVE COMPANIES
  • 14.8.3 DYNAMIC COMPANIES
  • 14.8.4 STARTING BLOCKS
  • 14.8.5 COMPETITIVE BENCHMARKING: START-UPS/SMES, 2025
    • 14.8.5.1 List of start-ups/SMEs
    • 14.8.5.2 Competitive benchmarking of start-ups/SMEs
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT LAUNCHES AND APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 OTHER DEVELOPMENTS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 DEXCOM, INC.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product launches and approvals
      • 15.1.1.3.2 Deals
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Right to win
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses and competitive threats
  • 15.1.2 ABBOTT
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product launches and approvals
      • 15.1.2.3.2 Deals
      • 15.1.2.3.3 Other developments
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Right to win
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses and competitive threats
  • 15.1.3 MASIMO
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product launches and approvals
      • 15.1.3.3.2 Deals
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Right to win
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses and competitive threats
  • 15.1.4 BD
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product launches and approvals
      • 15.1.4.3.2 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Right to win
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses and competitive threats
  • 15.1.5 APPLE INC.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product launches and approvals
      • 15.1.5.3.2 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Right to win
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses and competitive threats
  • 15.1.6 BOSTON SCIENTIFIC CORPORATION
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Deals
  • 15.1.7 IRHYTHM TECHNOLOGIES, INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product launches and approvals
      • 15.1.7.3.2 Deals
  • 15.1.8 KONINKLIJKE PHILIPS N.V.
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product launches and approvals
      • 15.1.8.3.2 Deals
      • 15.1.8.3.3 Other developments
  • 15.1.9 MEDTRONIC
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Deals
  • 15.1.10 BIOINTELLISENSE, INC.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product launches and approvals
      • 15.1.10.3.2 Deals
  • 15.1.11 F. HOFFMANN-LA ROCHE LTD
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product launches and approvals
  • 15.1.12 GE HEALTHCARE
    • 15.1.12.1 Business overview
    • 15.1.12.2 Products offered
    • 15.1.12.3 Recent developments
      • 15.1.12.3.1 Product launches and approvals
      • 15.1.12.3.2 Deals
  • 15.1.13 BIOBEAT
    • 15.1.13.1 Business overview
    • 15.1.13.2 Products offered
    • 15.1.13.3 Recent developments
      • 15.1.13.3.1 Product launches and approvals
      • 15.1.13.3.2 Deals
      • 15.1.13.3.3 Other developments
  • 15.1.14 EMPATICA INC.
    • 15.1.14.1 Business overview
    • 15.1.14.2 Products offered
    • 15.1.14.3 Recent developments
      • 15.1.14.3.1 Product launches and approvals
      • 15.1.14.3.2 Deals
  • 15.1.15 VITALCONNECT
    • 15.1.15.1 Business overview
    • 15.1.15.2 Products offered
    • 15.1.15.3 Recent developments
      • 15.1.15.3.1 Deals
      • 15.1.15.3.2 Other developments
  • 15.1.16 AMETRIS, LLC
    • 15.1.16.1 Business overview
    • 15.1.16.2 Products offered
    • 15.1.16.3 Recent developments
      • 15.1.16.3.1 Deals
  • 15.1.17 ALIVECOR, INC.
    • 15.1.17.1 Business overview
    • 15.1.17.2 Products offered
    • 15.1.17.3 Recent developments
      • 15.1.17.3.1 Product launches and approvals
      • 15.1.17.3.2 Deals
  • 15.1.18 WITHINGS
    • 15.1.18.1 Business overview
    • 15.1.18.2 Products offered
    • 15.1.18.3 Recent developments
      • 15.1.18.3.1 Product launches and approvals
      • 15.1.18.3.2 Deals
  • 15.1.19 VIVALNK, INC.
    • 15.1.19.1 Business overview
    • 15.1.19.2 Products offered
    • 15.1.19.3 Recent developments
      • 15.1.19.3.1 Product launches and approvals
  • 15.1.20 MEDIBIOSENSE
    • 15.1.20.1 Business overview
    • 15.1.20.2 Products offered
    • 15.1.20.3 Recent developments
      • 15.1.20.3.1 Product launches and approvals
• 15.2 OTHER PLAYERS
  • 15.2.1 SIBEL HEALTH, INC.
  • 15.2.2 BYTEFLIES
  • 15.2.3 STRADOS LABS
  • 15.2.4 ONERA TECHNOLOGIES B.V.
  • 15.2.5 EPICORE BIOSYSTEMS, INC.

16 RESEARCH METHODOLOGY

• 16.1 RESEARCH APPROACH
  • 16.1.1 SECONDARY RESEARCH
    • 16.1.1.1 Key data from secondary sources
  • 16.1.2 PRIMARY RESEARCH
    • 16.1.2.1 Primary sources
    • 16.1.2.2 Key data from primary sources
    • 16.1.2.3 Breakdown of primary interviews
    • 16.1.2.4 Insights from primary experts
• 16.2 RESEARCH METHODOLOGY DESIGN
• 16.3 MARKET SIZE ESTIMATION
• 16.4 DATA TRIANGULATION
• 16.5 RESEARCH ASSUMPTIONS
• 16.6 RESEARCH LIMITATIONS
  • 16.6.1 METHODOLOGY-RELATED
  • 16.6.2 SCOPE-RELATED
• 16.7 RISK ASSESSMENT

17 APPENDIX

• 17.1 DISCUSSION GUIDE
• 17.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 17.3 CUSTOMIZATION OPTIONS
• 17.4 RELATED REPORTS
• 17.5 AUTHOR DETAILS